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We will focus on two issues, both involving, but not confined to FK-506: first, the 
meaning of the graft acceptance, which is, after all, the objective ofimmunosuppression 
for the transplant surgeon; and second, how to take the next great step of xenotrans-
plantation. 
GRAFf ACCEPTANCE 
In June 1992 we published what is a new definition of graft acceptance. I Within 
a few minutes after the transplantation of any whole organ (as in the intestine) (FIG. 
1), a brisk two-way cell traffic starts in which dendritic and lymphoid cells from 
the recipient move into and become an integral part of the graft. With effective 
immunosuppression, the result in the intestine is the formation of a graft chimera, in 
which the epithelium remains of donor HL-A phenotype, while the lymphoreticular 
stroma (including lamina propria, Peyer's patches, and mesenteric nodes) becomes 
principally that of the recipient. 2,3 This important discovery was reported only 14 
months ago. Previously, only the liver, which is rich in these migratory cells, was 
known to be chimeric/'s but in the past year, it has been realized that the same thing 
occurs with all organs. Furthermore, at the same time as the graft becomes a chimera, 
the replaced donor dendritic and lymphoid cells leave the graft and are seeded through-
out the body of the recipient. I 
In the human cases in which cell migration, repopulation, and chimerism were 
proved, the first evidence with immunocytochemical (monoclonal) techniques was 
confirmed in all cases with polymerase chain reaction (PCR) studies. For example, the 
PCR band of a donor-specific HL·A allele was demonstrated in biopsy specimens of 
-This work was aided by Project Grant No. DK 29961 from the National Institutes of Health, 
Bethesda, Maryland. 
b Address for correspondence: Thomas E. Starzl, M.D., Ph.D., Department of Surgery, 3601 
Fifth Avenue, 5C Falk Clinic, University of Pittsburgh, Pittsburgh, Pennsylvania 15213. 
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GRAFT VS. HOST 
REJECTION 
FIGURE 1. The cell migration and repopulation that occurs after the transplantation of any 
whole organ.l These phenomena and the consequent chimerism were first seen after intestinal2,3 
and Iiver4,5 transplantation. 
the liver, skin, and heart of the liver recipients years after transplantation, 1 In fact, 
systemic chimerism was easily detected in all 17 liver recipients studied from 1l~ to 
22 years after transplantation. 
Organ grafts like the kidney and heart that are less well endowed with lymphoid 
tissue, but that contain dendritic cells go through the same process after transplanta-
tion, but on a smaller scale and with less easily detected chimerism, A few weeks ago, 
three of the longest-surviving kidney allograft recipients in the world underwent biopsy 
of their kidney allograft and their own skin and lymph nodes 28 to O9~ years after 
successful kidney transplantation had been carried out at the University ofColorado.6 
Because they had one or two haplotype HLA mismatches with their donors (and also 
in one case a different-sex donor), chimerism in the lymph nodes and skin could be 
detected with anti-HLA monoclonal antibodies and Y probes and confirmed with 
PCR. How redistributed donor dendritic cells survive this long, presumably involving 
clonal expansion initially and then chronic self-renewal, remains to be explained. The 
most conventional explanation is that dormant stem cells were in the grafts and were 
stimulated to respond by perioperative factors, of which Gm-CSF has been identified 
as a possibility in a recent paper from Inaba and Steinman et aL 7 A heretical possibility 
that cannot be dismissed out of hand is that the bone marrow-derived dendritic cell, 
once known as the passenger leukocyte, can dedifferentiate back to a pluripotent stem 
cell. 
These important but unresolved matters aside, the bottom line is that cell migration 
is the secret of graft acceptance and a prime reason for drug efficacy. It is the explanation 
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for the two phenomena described in the title of our 1963 article that was the beginning 
of clinical kidney transplantation at a practical level-the reversal of rejection by 
steroids and the subsequent ability to reduce the intensity of immunosuppression 
(referred to as tolerance). 6 The consequences of the cell migration and repopulation 
were still demonstrable three decades later in these same patients. In retrospect, the 
extent of this cell movement was evident from the results of exhaustive skin test studies 
by two young immunologists, W. E. C. Wilson and Charlie Kirkpatrick, who were 
working with us, and by Dave Talmage in Denver. Nearly 80% (77% to be exact) of 
the skin reactions that were positive in the donor, but not the recipient crossed over 
to the previously negative recipient, along with the transplanted kidney.8 When this 
did not occur (in the other 23%), it meant that the kidney transplant had failed. 
Kirkpatrick and Wilson speculated that the migration shown in the skin tests was 
"caused by adoptive transfer of donor cellular immunity by leukocytes in the renal 
vasculature and hilar lymphoid tissue." Unfortunately, these observations were made 
four years before Steinmuller showed the extent of intrarenal passenger leukocytes9 
and 10 years before these leukocytes were identified by Steinman and CohnlO as 
dendritic cells. Consequently, the skin test transfer could not be fully interpreted and 
eventually was attributed to "transfer factor,''8 a subject on which the same Charlie 
Kirkpatrick has presented a paper in this volume. 
However, even without a consensus explanation for rejection reversal and for what 
we had called tolerance in these early patients seen in Colorado, these observations, 
which soon were confirmed elsewhere, led to the empiric therapeutic dogma upon 
which our specialty of solid organ transplantation is based. The dogma calls for daily 
baseline treatment (in those days with azathioprine) plus intervention with the highly 
dose-maneuverable adrenal cortical steroids or antilymphoid agents to whatever level 
is required to maintain stable graft function. This creates a trial and potential error 
situation for every patient as dru~ are weaned. Although the new dru~ that have 
been added through the years have been increasingly potent, they can be viewed as 
traffic directors-allowing the cell movement that was first emphasized in the classical 
studies of Pekka Hayry of Helsinki, II but preventing the immune destruction that is 
the natural purpose of the traffiC. 12 In principle, it does not matter exactly how the 
immune reaction is disrupted, but only that this be achieved without killing all of the 
migratory cells. The inactivated but living cells that normally cause graft immunogenic-
ity and rejection become instead the missionaries subserving chimerism, graft accept-
ance, and ultimately tolerance. 
THE XENOGRAFf BARRIER 
The function of the lymphocyte can be disrupted at the level of antigen processing 
(claimed at one time for the drug deoxyspergualin), at an early stage in T cell activation 
as occurs with cyclosporine and FK-506, or distal to this with rapamycin, which does 
not inhibit the secretion of cytokines including 11..-2 but blocks their action. The so-
called antiproliferative antimetabolite dru~I of which azathioprine was the prototype, 
affect the immunocytes even more distally. 
How these dru~ work can be determined by isolating lymphocytes from biopsy 
specimens of rejecting organs and showing that these lymphocytes are suppressed with 
a given drug, and by measuring the cytokine content in the medium. 13,14 One of the 
first observations made with FK-506 was its ability to suppress clones of lymphocytes 
in cases of intractable rejection that had escaped under cyclosporine treatment. Subse-
quently, FK-506 clinical trials began in 1989 with "rescue" of recipients whose downhill 
course was arrested with this drug. IS Slightly more than three years later, FK-506 has 
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TABLE 1. Graft SurvivalR 
Without FK-506 With FK-506 
Survial > Survival > 
Group Treatmentb n 30 days n 30 days 
Heart graft 1 None 6 0 
2 FK506 6 0 
3 RS-61443 4 0 6 5 
4 BQR 6 1 5 5 
5 Cyclophosphamide 5 0 5 5 
6 Cyclophosphamide 5 0 5 5 
liver graft 7 None 8 0 
8 FK506 10 5 
9 RS-61443 5 0 10 9 
10 BQR 7 1 7 6 
11 Cyclophosphamide 5 0 10 9 
12 Cyclophosphamide 5 0 15 12 
NOTE: Animals alive at 30 days survived as long as FK-506 was continued out of 100 days no 
matter what the adjuvant induction drug . 
• These experiments are a fraction of those performed. A full account of this work as well as 
the testing of numerous other compounds is provided in Ref. 16. 
b Daily dose (mg/kg): for FK-506 was 2.0 X 6, 1.0 X 25 (heart) or 1.0 X 30 (liver), and 
0.5 on alternate day thereafter; for RS-61443 was 20.0 X 15 (14) starting day before Tx (heart) 
or day of Tx (liver); for BQR was 4.0 X 3 and 3.0 X 12 starting day before Tx (heart) or 
3.0 X 14 statting day ofTx (liver); and for cyclophosphamide was 7.5 X 15 (14) starting day 
before Tx (heart) or day ofTx (liver), except in Group 6 and 12, for which one dose of 80 mg 
was given 10 days preoperatively. 
become the brooding giant of baseline immunosuppression that has allowed clinical 
intestinal transplantation to move onto center stage and may allow xenotransplantation 
to go forward in the way that I will desctibe now. 
Ironically, the key drugs other than FK-506 that can unlock this door have been 
in our hands for more than 30 years. 16 They belong to the class of antiproliferative 
drugs that block enzymes required for the synthesis of tibonucleotides and thereby 
inhibit the DNA synthesis without which the final step of clonal lymphocyte expansion 
cannot proceed normally. All of these agents affect both T and B lymphocytes, but 
with some specificity. For example, azathioptine is more T cell-directed, as is discussed 
elsewhere in this volume, and cyclophosphamide has a greater anti-B cell effect. 
Although the duality of humoral and cellular mechanisms of xenograft rejection 
has been common knowledge for years, the antibody component has been refractory 
to treatment. For example, a hamster heart is confronted in the rat by a moderate titer 
(1:16-1:32) of preformed heterospecific cytotoxic antibodies and subsequently by a 
rapidly gathering antibody storm that destroys abdominally placed cardiac grafts within 
three days in untreated recipients, before there is a trace histopathologically ofimmuno-
cyte infiltration. By itself, FK-506, which prevents T cell activation and cytokine 
secretion, can prolong survival by only one day (TABLE 1). Monotherapy with either 
of two experimental "antiproliferative" drugs, RS-61443 and Brequinar, which suppress 
purine or pyrimidine nucleotide synthesis, respectively, tripled or quadrupled survival, 
but did not permit consistent chronic survival. 16 
However, when either of these two antimetabolite drugs or, more importantly, 
when the conventional anticancer drug cyclophosphamide was added to FK-506 for 
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the first two postoperative weeks, extended survival under continued FK-506 alone 
became routinely possible (TABLE 1). It was particularly noteworthy in the hamster-
rat expetiments that a single large dose of cyclophosphamide 10 days before transplanta-
tion permitted 100% success with daily postoperative FK-506. With either heart or 
liver, success was correlated with the ability to prevent the antibody response. 
The conclusion from these studies is that prevention or mitigation ofheterospecific 
antibody rejection by interdiction of the B cell proliferative response with antimetabo-
lite drugs for a surprisingly short period after transplantation or even beforehand is 
the essential first step to successful xenotransplantation, and unmasks the potential of 
continuous therapy with T cell-directed immunosuppressants such as FK-506. Such 
combination therapy should be clinically applicable, providing the humoral antibodies 
do not act so rapidly that they cause hyperacute rejection in a matter of a few minutes 
or hours. This condition has been demonstrated empirically with baboon-to-human 
kidney17 and heart18 xenotransplantation. In 1963, six baboon-to-human renal xeno-
grafts functioned for 6 to 60 days. These organs (and two decades later, Baby Fae's 
baboon heart) eventually developed regional infarcts when the blood vessels developed 
these widespread occlusive lesions that were thought to be antibody-mediated. 
After breaking through the antibody barrier, the process of xenograft acceptance 
involves the cell migration and consequent systemic chimerism that I described for 
allografts at the beginning of this paper. With a monoclonal antibody that recognizes 
LEW rat, but not hamster cells, we have shown that recipient dendritic and lymphoid 
cells are incorporated into heart or liver xenografts examined 100 days after transplanta-
tion. The displaced cells leaving these organs were ubiquitously distributed throughout 
the recipient where they could be detected easily with polyclonal anti-hamster antibo-
dies and confirmed with polymerase chain reaction (peR) technique. 
This means that successful clinical xenotransplantation must be visualized along 
the same lines of the donor-recipient cellular intimacy that I described at the outset 
to be the fundamental means of allograft acceptance. To some this will be apocryphal, 
and to others it will define the magnificent unity of biology. 
CONCLUSION 
These and other viewpoints were considered at the University of Pittsburgh for 
two-thirds of a year before the decision was made to proceed with the baboon-to-
human liver transplantation that took place there in 1992, just after this symposium 
ended. There was no more appropriate forum to have made these plans known in 
advance and to provide their justifications than at this remarkable meeting of scientists. 
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